Catalog No.
VVV00302
Species reactivity
SARS-CoV-2
Host species
Human
Isotype
IgG1, kappa
Clonality
Monoclonal
Target
Spike glycoprotein, S glycoprotein, E2, Peplomer protein, RBD, Spike protein S1, S, Receptor-Binding Domain, SARS-CoV-2
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P0DTC2
Applications
Neutralization
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
1H1
Allostery Links hACE2 Binding, Pan-variant Neutralization and Helical Extension in the SARS-CoV-2 Spike Protein., PMID:40447075
Development of bivalent RBD adapted COVID-19 vaccines for broad sarbecovirus immunity., PMID:40442110
Cross-reactive sarbecovirus antibodies induced by mosaic RBD nanoparticles., PMID:40402246
An RBD-Fc mucosal vaccine provides variant-proof protection against SARS-CoV-2 in mice and hamsters., PMID:40383816
AI designed, mutation resistant broad neutralizing antibodies against multiple SARS-CoV-2 strains., PMID:40319133
A SARS-CoV and SARS-CoV-2 RBD Heterodimer Vaccine Candidate., PMID:40317517
Self-assembled epitope-based nanoparticles targeting the SARS-CoV-2 spike protein enhanced the immune response and induced potential broad neutralizing activity., PMID:40270771
Anti-S2 antibodies responsible for the SARS-CoV-2 infection-induced serological cross-reactivity against MERS-CoV and MERS-related coronaviruses., PMID:40226608
Immunogenicity and safety of monovalent and bivalent SARS-CoV-2 variant adapted RBD-based protein booster vaccines in adults previously immunized with different vaccine platforms: A phase II/III, randomized clinical trial., PMID:40179522
Regional dynamics and mechanisms behind SARS-CoV-2 XDV.1 prevalence in Chongqing via genomic surveillance and molecular insights., PMID:40139569
Development of Receptor-Integrated Magnetically Labeled Liposomes for Investigating SARS-CoV-2 Fusion Interactions., PMID:39925203
Immune evasion of Omicron variants JN.1, KP.2, and KP.3 to the polyclonal and monoclonal antibodies from COVID-19 convalescents and vaccine recipients., PMID:39864525
Cross-reactive sarbecovirus antibodies induced by mosaic RBD-nanoparticles., PMID:39803445
Discovery of a pan anti-SARS-CoV-2 monoclonal antibody with highly efficient infected cell killing capacity for novel immunotherapeutic approaches., PMID:39584380
A trivalent mucosal vaccine encoding phylogenetically inferred ancestral RBD sequences confers pan-Sarbecovirus protection in mice., PMID:39561781
Engineered bispecific antibodies with enhanced breadth and potency against SARS-CoV-2 variants and SARS-related coronaviruses., PMID:39520579
Broad cross neutralizing antibodies against sarbecoviruses generated by SARS-CoV-2 infection and vaccination in humans., PMID:39438493
Chemical Proteomics Approaches for Screening Small Molecule Inhibitors Covalently Binding to SARS-Cov-2., PMID:39410782
Structural basis for receptor-binding domain mobility of the spike in SARS-CoV-2 BA.2.86 and JN.1., PMID:39375326
Nanomechanical footprint of SARS-CoV-2 variants in complex with a potent nanobody by molecular simulations., PMID:39351797
Structure-guided in vitro evolution of nanobodies targeting new viral variants., PMID:39325826
Individuals carrying the HLA-B*15 allele exhibit favorable responses to COVID-19 vaccines but are more susceptible to Omicron BA.5.2 and XBB.1.16 infection., PMID:39257586
A head-to-head comparison of humoral and cellular immune responses of five COVID-19 vaccines in adults in China., PMID:39234239
Protective RBD-dimer vaccines against SARS-CoV-2 and its variants produced in glycoengineered Pichia pastoris., PMID:39213280
Pan-beta-coronavirus subunit vaccine prevents SARS-CoV-2 Omicron, SARS-CoV, and MERS-CoV challenge., PMID:39189731
A Click-Type Enzymatic Method for Antigen-Adjuvant Conjugation., PMID:39177201
Broad sarbecovirus neutralization by combined memory B cell antibodies to ancestral SARS-CoV-2., PMID:39071888
Universal subunit vaccine protects against multiple SARS-CoV-2 variants and SARS-CoV., PMID:39054338
Preparation and immunological activity evaluation of an intranasal protein subunit vaccine against ancestral and mutant SARS-CoV-2 with curdlan sulfate/O-linked quaternized chitosan nanoparticles as carrier and adjuvant., PMID:39002905
Deep repertoire mining uncovers ultra-broad coronavirus neutralizing antibodies targeting multiple spike epitopes., PMID:38848216
Immune responses and reinfection of SARS-CoV-2 Omicron variant in patients with lung cancer., PMID:38837354
Mosaic RBD nanoparticle elicits immunodominant antibody responses across sarbecoviruses., PMID:38748880
Inducing Long Lasting B Cell and T Cell Immunity Against Multiple Variants of SARS-CoV-2 Through Mutant Bacteriophage Qβ-Receptor Binding Domain Conjugate., PMID:38733291
Safety and immunogenicity of the SARS-CoV-2 LYB001 RBD-based VLP vaccine (CHO cell) phase 1 in Chinese adults: a randomized, double-blind, positive-parallel-controlled study., PMID:38695310
A chimeric adenovirus-vectored vaccine based on Beta spike and Delta RBD confers a broad-spectrum neutralization against Omicron-included SARS-CoV-2 variants., PMID:38680520
When Should I Get My Next COVID-19 Vaccine? Data From the Surveillance of Responses to COVID-19 Vaccines in Systemic Immune-Mediated Inflammatory Diseases (SUCCEED) Study., PMID:38621797
Rapid isolation of pan-neutralizing antibodies against Omicron variants from convalescent individuals infected with SARS-CoV-2., PMID:38510237
The receptor binding domain of SARS-CoV-2 Omicron subvariants targets Siglec-9 to decrease its immunogenicity by preventing macrophage phagocytosis., PMID:38454157
N-glycosylation of the SARS-CoV-2 spike protein at Asn331 and Asn343 is involved in spike-ACE2 binding, virus entry, and regulation of IL-6., PMID:38444370
Asialoglycoprotein receptor 1 promotes SARS-CoV-2 infection of human normal hepatocytes., PMID:38355848
Safety and Immunogenicity After Primary and Booster Inactivated SARS-Cov-2 Vaccination in Patients with Autoimmune Liver Diseases., PMID:38343613
A monoclonal antibody targeting a large surface of the receptor binding motif shows pan-neutralizing SARS-CoV-2 activity., PMID:38316751
Identification of a highly conserved neutralizing epitope within the RBD region of diverse SARS-CoV-2 variants., PMID:38287016
Caveats of chimpanzee ChAdOx1 adenovirus-vectored vaccines to boost anti-SARS-CoV-2 protective immunity in mice., PMID:38280035
Site-directed neutralizing antibodies targeting structural sites on SARS-CoV-2 spike protein., PMID:38128698
Mosaic RBD Nanoparticles Elicit Protective Immunity Against Multiple Human Coronaviruses in Animal Models., PMID:38105421
Heteromultimeric sarbecovirus receptor binding domain immunogens primarily generate variant-specific neutralizing antibodies., PMID:38096415
Deep immunoglobulin repertoire sequencing depicts a comprehensive atlas of spike-specific antibody lineages shared among COVID-19 convalescents., PMID:38044868
Vaccine-mediated protection against Merbecovirus and Sarbecovirus challenge in mice., PMID:37858337
Protection of the receptor binding domain (RBD) dimer against SARS-CoV-2 and its variants., PMID:37843372
For research use only. Not for human or drug use.
